EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.). Watch their discussion below or on Dr. Sophia’s website.
Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia
Jul 17, 2020 | Blog, News | 0 comments
EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies
by EVQLV | August 25, 2020 | News, Press Releases | 0 Comments
The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology
Demystifying AI In Pharma
by EVQLV | August 6, 2020 | Blog, News | 0 Comments
Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.
Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia
by Daniel Gigante | July 17, 2020 | Blog, News | 0 Comments
EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).
How Our Algorithm Models the Drug Discovery Process
by Daniel Gigante | July 14, 2020 | Blog | 0 Comments
Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.
Large Pharma’s Embrace of Artificial Intelligence
by Nick Skaliotos | July 10, 2020 | Blog | 1 Comment
The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.
0 Comments